Clinical trial · Interventional
Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma
Sentinel Lymph Node Biopsy in the Thyroid Carcinoma; Randomized, Prospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Occult lymph node metastasis is common in micro papillary thyroid cancer. However, the role of lymph node dissection in the treatment of microPTC remains controversial. The investigators want to investigate the usefulness routine central dissection and sentinel lymph node biopsy in prognosis of micro PTC. This is a prospective randomized control study. The investigators started this study from May of 2009 and this study will be continued until Dec. 2011.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma | Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Routine central neck dissection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- C group
- description
- Routine central neck dissection
- interventionNames
- Procedure: Routine central neck dissection
- type
- NO_INTERVENTION
- label
- N group
- description
- No central neck node dissection
Primary outcomes (1)
- measure
- Is routine neck node dissection necessary in micro PTC?
- timeFrame
- Until 5 year follow-up. (Dec. 2016)
- description
- To see the necessity of routine neck node dissection in micro PTC, we will compare the recurrence rate and other complication (e.g. hoarseness and hypocalcemia) between group I(no dissection) and group III(routine dissection) after completion of study(after 5 year f/u). To check the safety of this study, our result will be checked by korea institutional reveiw board every one year.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * papillary carcinoma of thyroid (less than 4cm) * no evidence of lymph node metastasis in preoperative work-up result * the patients who accept this study Exclusion Criteria: * large thyroid cancer( \> 4cm) * morbid * anticoagulation agent usage * endoscopic or robotic thyroid operation * evidence of lymph node metastasis or extrathyroidal extension in preoperative US and CT scan
References
Publications (0)
Data not yet available